Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/01/00 |
David Innes
IRC | Investor Relations Contact | - | 26/02/19 |
General Counsel | 78 | 01/06/11 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Navid Malik
BRD | Director/Board Member | 55 | 01/04/12 |
Director/Board Member | 74 | 27/01/16 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 0 | 1 300 000 | 0 | 0 | 90,82 % |
Azione B | 1 | 1 208 177 416 | 1 097 287 981 ( 90,82 %) | 0 |
Coordinate società
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSettore
Variaz. 1 gen. | Capi. | |
---|---|---|
+9,58% | 115 Mrd | |
+12,41% | 106 Mrd | |
-2,59% | 21,96 Mrd | |
-12,38% | 21,87 Mrd | |
-5,29% | 19,21 Mrd | |
-3,35% | 18,08 Mrd | |
-38,57% | 17,71 Mrd | |
+7,51% | 14,32 Mrd | |
+35,67% | 12,42 Mrd |